You are on page 1of 11

Development of a vaccine to treat

dengue types and test their effect.

Present :
Miguel de Jesus Reyes Castillo
Miguel Angel Escalera Lugo
Yosselin Irazar Perez Rodriguez
Jonathan Silva Mendoza
Abdiel Eleuterio Guerrero

Flaviviridae, ARN
Aedes aegypti
single chain +

DEN-1, DEN-2,
DEN-3, DEN-4
At present it is a problem in several countries of Latin America because its
incidence has increased in the last decades. It has caused about 1181 deaths,
only in America.
Materials and methods
Obtaining of strains West pac 74
(DEN-1), S16803, (DEN-2), CH53489
(DEN-3), TVP360 (DEN-4)

Cells were trypsinized

Adaptation of VERO cells and subcultured
Growth medium (5
Inoculation of the
Growth medium
Preparation of antigens
Virus concentration by tangential
flow ultrafiltration

Sucrose gradient ultracentrifugation


Incubation for
Virus inactivation with formalin
approximately 15 days
Evaluation of

Virus plaque reduction

neutralization (PRNT)
Inoculation of vaccines in monkeys

1.- 15 macaques rhesus were randomly assigned to 3 groups of 5 individuals each.

2.- Each one received formulations of the vaccine or saline solution, with 30 days
3. One group received formulations of the vaccine with doses of antigen plus
adjuvant (aluminum hydroxide)
4.- Another group received the formulation of the vaccine without adjuvant
5. A negative control group received phosphate buffered saline (PBS)
6. The dengue virus (DEN-1-DEN-4) was inoculated in each monkey.
7.- Monkeys health status is monitored every day.
the adjuvants are heterogeneous and nonspecific agents that associated
with the vaccine antigens induce a more powerful and prolonged immune

Blaney JE Jr, Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS, 2007. Vaccine
candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes
of rDEN4 and rDEN4 DEN1. Virol J 4: 23
Fernandez S, Cisney ED, Tikhonov AP, Schweitzer B, Putnak RJ, Simmons M, Ulrich RG, 2011.
Antibody recognition of the dengue virus proteome and implications for development of
vaccines. Clin Vaccine Immunol 18: 523 532
Simmons M, Burgess T, Lynch J, Putnak R, 2010. Protection against dengue virus by non-
replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Virology 396: 280288.
Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ,
Endy TP, 2006. Protection of rhesus monkeys against dengue virus challenge after
tetravalent live attenuated dengue virus vaccination. J Infect Dis 193: 16581665.
Stefan Fernandez, Stephen J. Thomas, Rafael De La Barrera, Rawiwan Im-erbsin, Richard G.
Jarman, Benot Baras, Jean-Franois Toussaint, Sally Mossman, Bruce L. Innis, Alexander
Schmidt, Marie-Pierre Malice, Pascale Festraets, Lucile Warter, J. Robert Putnak, and
Kenneth H. Eckels*, 2015. An Adjuvanted, Tetravalent Dengue Virus-Purified Inactivated
Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against
Dengue Challenge in Rhesus Macaques